Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 475
Rating:

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

Prof Alexander Perl speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the updated results from the AMIRAL study looking at the use of gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia (AML).

He explains that patients were randomised 2:1 to either single agent gilteritinib or investigator's choice standard chemotherapy.

Prof Perl explains that the gilteritinib arm showed higher response rates and also improved survival.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

CML Life Banner


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation